Nonsteroidal anti-inflammatory drugs for retinal disease

International Journal of Inflammation

Volumn 2013, Issue , 2013, Pages

  Schoenberger, Scott D ^a   Kim, Stephen J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFENAC; BEVACIZUMAB; BROMFENAC; CORTICOSTEROID; DICLOFENAC; FLUOROMETHOLONE; FLURBIPROFEN; KETOROLAC; KETOROLAC TROMETAMOL; MELOXICAM; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RANIBIZUMAB; SULINDAC; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

CATARACT EXTRACTION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; IC 50; MEIOSIS; PHOTODYNAMIC THERAPY; PHOTOPHOBIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROPHYLAXIS; REFRACTIVE SURGERY; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; REVIEW; VITREORETINAL SURGERY;

EID: 84876511818     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2013/281981     Document Type: Review

References (86)

1. Kim S. J., Flach A. J., Jampol L. M., Nonsteroidal anti-inflammatory drugs inophthalmology. Survey of Ophthalmology 2010 55 2 108 133 2-s2.0-75949096248 10.1016/j.survophthal.2009.07.005
2. Shelsta H. N., Jampol L. M., Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina 2011 31 1 4 12 2-s2.0-78651356165 10.1097/IAE.0b013e3181fd9740
3. Simmons D. L., Botting R. M., Hla T., Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004 56 3 387 437 2-s2.0-4143107932 10.1124/pr.56.3.3 (Pubitemid 39096597)
4. Davies N. M., Good R. L., Roupe K. A., Yáñez J. A., Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?-not as easy as 1, 2, 3. Journal of Pharmacy and Pharmaceutical Sciences 2004 7 2 217 226 2-s2.0-12844253982 (Pubitemid 41528895)
5. Chin M. S., Nagineni C. N., Hooper L. C., Detrick B., Hooks J. J., Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science 2001 42 10 2338 2346 2-s2.0-0034848585 (Pubitemid 32848864)
6. Shinomiya S., Naraba H., Ueno A., Utsunomiya I., Maruyama T., Ohuchida S., Ushikubi F., Yuki K., Narumiya S., Sugimoto Y., Ichikawa A., Oh-ishi S., Regulation of TNF α and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochemical Pharmacology 2001 61 9 1153 1160 2-s2.0-17044447324 10.1016/S0006-2952(01)00586-X (Pubitemid 32285482)
7. Cheng T., Cao W., Wen R., Steinberg R. H., LaVail M. M., Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Investigative Ophthalmology and Visual Science 1998 39 3 581 591 2-s2.0-0031594643 (Pubitemid 28110692)
8. Reddy R., Kim S. J., Critical appraisal of ophthalmic ketorolac in the treatment of pain and inflammation following cataract surgery. Clinical Ophthalmology 2011 5 751 758
9. Ahuja M., Dhake A. S., Sharma S. K., Majumdar D. K., Topical ocular delivery of NSAIDs. The AAPS Journal 2008 10 2 229 241 2-s2.0-53849143939 10.1208/s12248-008-9024-9
10. Riendeau D., Charleson S., Cromlish W., Mancini J. A., Wong E., Guay J., Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Canadian Journal of Physiology and Pharmacology 1997 75 9 1088 1095 2-s2.0-0030733305 (Pubitemid 27504776)
11. Gamache D. A., Graff G., Brady M. T., Spellman J. M., Yanni J. M., Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti- inflammatory efficacy. Inflammation 2000 24 4 357 370 2-s2.0-0034045508 10.1023/A: 1007049015148 (Pubitemid 30367882)
12. Waterbury L. D., Silliman D., Jolas T., Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Current Medical Research and Opinion 2006 22 6 1133 1140 2-s2.0-33745685717 10.1185/030079906X112471 (Pubitemid 44000733)
13. Walters T., Raizman M., Ernest P., Gayton J., Lehmann R., In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. Journal of Cataract and Refractive Surgery 2007 33 9 1539 1545 2-s2.0-34548142929 10.1016/j.jcrs.2007.05.015 (Pubitemid 47299180)
14. Ellis P. P., Pfoff D. S., Bloedow D. C., Riegel M., Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. Journal of Ocular Pharmacology 1994 10 4 677 682 2-s2.0-0028609425
15. Attar M., Schiffman R., Borbridge L., Farnes Q., Welty D., Ocular pharmacokinetics of 0.45% ketorolac tromethamine. Clinical Ophthalmology 2010 4 1 1403 1408 2-s2.0-78650705220 10.2147/OPTH.S15146
16. Bucci F. A. Jr., Waterbury L. D., Amico L. M., Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. American Journal of Ophthalmology 2007 144 1 146 147 2-s2.0-34250723434 10.1016/j.ajo.2007.02.034 (Pubitemid 46963171)
17. Heier J. S., Awh C. C., Busbee B. G., Waterbury L. D., Daniel P., Stoller G. L., Cleary T. S., Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina 2009 29 9 1310 1313 2-s2.0-70350161079 10.1097/IAE.0b013e3181b094e6
18. Irvine S. R., A newly defined vitreous syndrome following cataract surgery. American Journal of Ophthalmology 1953 36 5 499 619 2-s2.0-77049136556
19. Kim S. J., Equi R., Bressler N. M., Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007 114 5 881 889 2-s2.0-34247401025 10.1016/j.ophtha.2006.08.053 (Pubitemid 46635831)
20. Lobo C. L., Faria P. M., Soares M. A., Bernardes R. C., Cunha-Vaz J. G., Macular alterations after small-incision cataract surgery. Journal of Cataract and Refractive Surgery 2004 30 4 752 760 2-s2.0-16544366754 10.1016/S0886- 3350(03)00582-0 (Pubitemid 38501467)
21. Ursell P. G., Spalton D. J., Whitcup S. M., Nussenblatt R. B., Cystoid macular edema after phacoemulsification: relationship to blood- aqueous barrier damage and visual acuity. Journal of Cataract and Refractive Surgery 1999 25 11 1492 1497 2-s2.0-0032693316 10.1016/S0886-3350(99)00196-0 (Pubitemid 29523175)
22. Warren K. A., Bahrani H., Fox J. E., NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010 30 2 260 266 2-s2.0-76749101160 10.1097/IAE.0b013e3181b8628e
23. Hariprasad S. M., Akduman L., Clever J. A., Ober M., Recchia F. M., Mieler W. F., Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clinical Ophthalmology 2009 3 1 147 154 2-s2.0-77949575051
24. Flach A. J., Stegman R. C., Graham J., Kruger L. P., Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990 97 10 1253 1258 2-s2.0-0025047843 (Pubitemid 20353967)
25. Miyake K., Masuda K., Shirato S., Oshika T., Eguchi K., Hoshi H., Majima Y., Kimura W., Hayashi F., Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Japanese Journal of Ophthalmology 2000 44 1 58 67 2-s2.0-0033973488 10.1016/S0021-5155(99)00176-8 (Pubitemid 30029136)
26. Wittpenn J. R., Silverstein S., Heier J., Kenyon K. R., Hunkeler J. D., Earl M., A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs. steroid alone in low-risk cataract surgery patients. American Journal of Ophthalmology 2008 146 4 554 560 2-s2.0-51649089809 10.1016/j.ajo.2008.04.036
27. Kim S. J., Bressler N. M., Optical coherence tomography and cataract surgery. Current Opinion in Ophthalmology 2009 20 1 46 51 2-s2.0-58149264987 10.1097/ICU.0b013e3283199162
28. Flach A. J., Kraff M. C., Sanders D. R., Tanenbaum L., The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Archives of Ophthalmology 1988 106 4 480 483 2-s2.0-0023950402
29. Kim S. J., Lo W. R., Hubbard G. B., Srivastava S. K., Denny J. P., Martin D. F., Yan J., Bergstrom C. S., Cribbs B. E., Schwent B. J., Aaberg T. M., Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Archives of Ophthalmology 2008 126 9 1203 1208 2-s2.0-51649106232 10.1001/archopht.126.9.1203
30. Schoenberger S. D., Miller D. M., Petersen M. R., Foster R. E., Riemann C. D., Sisk R. A., Nepafenac for epiretinal membrane surgery. Ophthalmology 2011 118 7 1482.e1 1482.e3 2-s2.0-79959946437 10.1016/j.ophtha.2011.01.034
31. Naithani P., Puranik S., Vashisht N., Khanduja S., Kumar S., Garg S., Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery. Retina 2012 32 2 250 255 10.1097/IAE.0b013e31821e2057
32. Friedman D. S., O'Colmain B. J., Munoz B., Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004 122 4 564 572 10.1001/archopht.122.4.564 (Pubitemid 38456293)
33. Brown G. C., Brown M. M., Sharma S., Stein J. D., Roth Z., Campanella J., Beauchamp G. R., Ferris F. L., Lindstrom R. L., Wilson M. E., Traboulsi E. I., Anderson D. R., Feldon S. E., Bateman J. B., Meredith T. A., The burden of age-related macular degeneration: a value-based medicine analysis. Transactions of the American Ophthalmological Society 2005 103 173 186 2-s2.0-29944432478 (Pubitemid 43042108)
34. Folk J. C., Stone E. M., Ranibizumab therapy for neovascular age-related macular degeneration. New England Journal of Medicine 2010 363 17 1648 1655 2-s2.0-77958599577 10.1056/NEJMct1000495
35. Yourey P. A., Gohari S., Su J. L., Alderson R. F., Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. Journal of Neuroscience 2000 20 18 6781 6788 2-s2.0-0034666284
36. Zarbin M. A., Current concepts in the pathogenesis of age-related macular degeneration. Archives of Ophthalmology 2004 122 4 598 614 2-s2.0-1842478123 10.1001/archopht.122.4.598 (Pubitemid 38456297)
37. Patel M., Chan C. C., Immunopathological aspects of age-related macular degeneration. Seminars in Immunopathology 2008 30 2 97 110 2-s2.0-42449105692 10.1007/s00281-008-0112-9
38. Maloney S. C., Fernandes B. F., Castiglione E., Antecka E., Martins C., Marshall J. C., Di Cesare S., Logan P., Burnier M. N., Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina 2009 29 2 176 180 2-s2.0-63249116911 10.1097/IAE.0b013e3181884fa6
39. Monnier Y., Zaric J., Rüegg C., Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Current Drug Targets: Inflammation and Allergy 2005 4 1 31 38 2-s2.0-17844404586 10.2174/1568010053622975 (Pubitemid 40584850)
40. Gately S., Kerbel R., Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Progress in Experimental Tumor Research 2003 37 179 192 2-s2.0-0042131613 (Pubitemid 36767986)
41. Wu W. K. K., Sung J. J., Lee C. W., Yu J., Cho C. H., Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Letters 2010 295 1 7 16 2-s2.0-77953611147 10.1016/j.canlet.2010.03.015
42. Yanni S. E., Barnett J. M., Clark M. L., Penn J. S., The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Investigative Ophthalmology and Visual Science 2009 50 11 5479 5486 2-s2.0-77953359022 10.1167/iovs.09-3652
43. Amrite A. C., Ayalasomayajula S. P., Cheruvu N. P. S., Kompella U. B., Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Investigative Ophthalmology and Visual Science 2006 47 3 1149 1160 2-s2.0-33645403444 10.1167/iovs.05-0531 (Pubitemid 46768351)
44. Takahashi K., Saishin Y., Saishin Y., Mori K., Ando A., Yamamoto S., Oshima Y., Nambu H., Melia M. B., Bingaman D. P., Campochiaro P. A., Topical nepafenac inhibits ocular neovascularization. Investigative Ophthalmology and Visual Science 2003 44 1 409 415 2-s2.0-0037247719 10.1167/iovs.02-0346 (Pubitemid 36134303)
45. Kim S. J., Toma H. S., Barnett J. M., Penn J. S., Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Experimental Eye Research 2010 91 4 537 543 10.1016/j.exer.2010.07.011
46. Kim S. J., Toma H. S., Inhibition of choroidal neovascularization by intravitreal ketorolac. Archives of Ophthalmology 2010 128 5 596 600 2-s2.0-77952122491 10.1001/archophthalmol.2010.69
47. Rezaei K. A., Toma H. S., Cai J., Penn J. S., Sternberg P., Kim S. J., Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice. Investigative Ophthalmology and Visual Science 2011 52 2 701 707 2-s2.0-79953275698 10.1167/iovs.10-6319
48. Hu W., Criswell M. H., Ottlecz A., Cornell T. L., Danis R. P., Lambrou G. N., Ciulla T. A., Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina 2005 25 8 1054 1064 2-s2.0-33644874658 10.1097/00006982-200512000-00015 (Pubitemid 44735104)
49. Takahashi H., Yanagi Y., Tamaki Y., Uchida S., Muranaka K., COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochemical and Biophysical Research Communications 2004 325 2 461 466 2-s2.0-7644236908 10.1016/j.bbrc.2004.10.054 (Pubitemid 39458017)
50. McGeer P. L., Sibley J., Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiology of Aging 2005 26 8 1199 1203 2-s2.0-19444361805 10.1016/j.neurobiolaging.2005.02.003 (Pubitemid 40726013)
51. Wilson H. L., Schwartz D. M., Bhatt H. R. F., McCulloch C. E., Duncan J. L., Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. American Journal of Ophthalmology 2004 137 4 615 624 2-s2.0-1842451938 10.1016/j.ajo.2003.10.025 (Pubitemid 38446673)
52. Wang J. J., Mitchell P., Smith W., Gillies M., Billson F., Blue Mountains Eye Study, Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiology 2003 10 1 37 48 2-s2.0-0037294392 10.1076/opep.10.1.37.13776 (Pubitemid 36315383)
53. Zweifel S. A., Engelbert M., Khan S., Freund K. B., Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009 29 10 1527 1531 2-s2.0-73349105630 10.1097/IAE.0b013e3181b32f4c
54. Chen E., Benz M. S., Fish R. H., Brown D. M., Wong T. P., Kim R. Y., Major J. C., Use of nepafenac (Nevanac)in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clinical Ophthalmology 2010 4 1 1249 1252 2-s2.0-78650683541 10.2147/OPTH.S14092
55. Adjunctive Diclofenac with Verteporfin (ADD-V) Study Group, Boyer D. S., Beer P. M., Blodi B. A., Bradford R. H., Chen S., Googe J. M., Halperin L. S., Harvey P. T., Joffe L., Marx J. L., Mieler W. F., Vander J. F., Wong K. L., Yoser S. L., Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study. Retina 2007 27 6 693 700 2-s2.0-34447297551 10.1097/IAE.0b013e318030e519 (Pubitemid 47051764)
56. Grant C. A., Combination therapy: lucentis (ranibizumab injection) and xibrom (bromfenac ophthalmic solution) 0. 09% in the treatment of chroidal neovascular membrane secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science 2008 49. E-abstract 563
57. Flaxel C., Schain M. B., Hamon S. C., Francis P. J., Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration. Retina 2012 32 3 417 423
58. Gomi F., Sawa M., Tsujikawa M., Nishida K., Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 2012 32 9 1804 1810
59. Antonetti D. A., Klein R., Gardner T. W., Diabetic retinopathy. New England Journal of Medicine 2012 366 13 1227 1239 10.1056/NEJMra1005073
60. Bhagat N., Grigorian R. A., Tutela A., Zarbin M. A., Diabetic macular edema: pathogenesis and treatment. Survey of Ophthalmology 2009 54 1 1 32 2-s2.0-58449114090 10.1016/j.survophthal.2008.10.001
61. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995 102 4 647 661
62. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. United Kingdom Prospective Diabetes Study Group. British Medical Journal 1998 317 7160 703 713
63. Adamis A. P., Berman A. J., Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in Immunopathology 2008 30 2 65 84 2-s2.0-42449135678 10.1007/s00281-008-0111-x
64. Lange C. A., Stavrakas P., Luhmann U. F., Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. American Journal of Ophthalmology 2011 152 3 406 412
65. Suzuki Y., Nakazawa M., Suzuki K., Yamazaki H., Miyagawa Y., Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Japanese Journal of Ophthalmology 2011 55 3 256 263 2-s2.0-79960072567 10.1007/s10384-011-0004-8
66. Zhou J., Wang S., Xia X., Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Current Eye Research 2012 37 5 416 420 10.3109/02713683.2012.661114
67. Schoenberger S. D., Kim S. J., Sheng J., Rezaei K. A., Lalezary M., Cherney E., Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy and correlation with VEGF and inflammatory cytokines. Investigative Ophthalmology & Visual Science 2012 53 9 5906 5911
68. Cheng T., Cao W., Wen R., Steinberg R. H., LaVail M. M., Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Investigative Ophthalmology and Visual Science 1998 39 3 581 591 2-s2.0-0031594643 (Pubitemid 28110692)
69. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994 331 22 1480 1487 2-s2.0-0027942607 10.1056/NEJM199412013312203 (Pubitemid 24356306)
70. Johnson E. I. M., Dunlop M. E., Larkins R. G., Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Current Eye Research 1999 18 2 79 82 2-s2.0-0033023194 (Pubitemid 29137563)
71. Kern T. S., Miller C. M., Du Y., Zheng L., Mohr S., Ball S. L., Kim M., Jamison J. A., Bingaman D. P., Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007 56 2 373 379 2-s2.0-33847028707 10.2337/db05-1621
72. Ayalasomayajula S. P., Kompella U. B., Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. European Journal of Pharmacology 2003 458 3 283 289 2-s2.0-0037419532 10.1016/S0014-2999(02)02793-0 (Pubitemid 36009467)
73. Joussen A. M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., Adamis A. P., Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. The FASEB Journal 2002 16 3 438 440 2-s2.0-0036517850
74. Powell E. D., Field R., Diabetic retinopathy and rheumatoid arthritis. The Lancet 1964 284 7349 17 18 2-s2.0-50549220514
75. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991 98 5, supplement 757 765
76. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes 1989 38 4 491 498 2-s2.0-0024500488
77. Hattori Y., Hashizume K., Nakajima K., Nishimura Y., Naka M., Miyanaga K., The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Current Medical Research and Opinion 2007 23 8 1913 1917 2-s2.0-34548133077 10.1185/030079907X218770 (Pubitemid 47300390)
78. Chew E. Y., Kim J., Coleman H. R., Aiello L. P., Fish G., Ip M., Haller J. A., Figueroa M., Martin D., Callanan D., Avery R., Hammel K., Thompson D. J. S., Ferris F. L., Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina 2010 30 3 459 467 2-s2.0-77949393585 10.1097/IAE.0b013e3181bcf1a0
79. Bressler N. M., Edwards A. R., Beck R. W., Flaxel C. J., Glassman A. R., Ip M. S., Kollman C., Kuppermann B. D., Stone T. W., Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology 2009 127 12 1566 1571 2-s2.0-73349135368 10.1001/archophthalmol.2009.308
80. Hariprasad S. M., Callanan D., Gainey S., He Y. G., Warren K., Cystoid and diabetic macular edema treated with nepafenac 0.1%. Journal of Ocular Pharmacology and Therapeutics 2007 23 6 585 589 2-s2.0-36749083568 10.1089/jop.2007.0062 (Pubitemid 350204684)
81. Callanan D., Williams P., Topical nepafenac in the treatment of diabetic macular edema. Clinical Ophthalmology 2008 2 4 689 692
82. July 2012, http://clinicaltrials.gov/ct2/show/NCT01331005
83. Soheilian M., Karimi S., Ramezani A., Peyman G. A., Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010 30 3 509 515 2-s2.0-77949349000 10.1097/IAE. 0b013e3181bdfa43
84. Elbendary A. M., Shahin M. M., Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 2011 31 10 2058 2064 10.1097/IAE.0b013e31822a042a
85. Reis Ado C., Vianna R. N., Reis R. S., Cardoso G. P., Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation. Arquivos Brasileiros de Oftalmologia 2010 73 4 338 342 2-s2.0-78449238708 10.1590/S0004-27492010000400007
86. Maldonado R. M., Vianna R. N. G., Cardoso G. P., de Magalhães A. V., Burnier M. N. Jr., Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Current Eye Research 2011 36 8 768 773 2-s2.0-79960709309 10.3109/02713683.2011.585734